Specify a stock or a cryptocurrency in the search bar to get a summary
Kazia Therapeutics Ltd ADR
KZIAKazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. Address: Three International Towers, Sydney, NSW, Australia, 2000
Analytics
WallStreet Target Price
19.06 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures KZIA
Dividend Analytics KZIA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History KZIA
Stock Valuation KZIA
Financials KZIA
Results | 2019 | Dynamics |